Biolidics (SGX:8YY) has addressed queries from the Singapore Exchange regarding its recent issuance of 946 million new ordinary shares, according to a Monday filing on the Singapore Exchange.
Shares of the medical technology company were allocated to vendors Yuan Zhijun and Wu Kunwei before the completion of a proposed acquisition.
The company explained that the early issuance was necessitated by the listing and quotation notice's requirement to issue shares within seven market days.
Additionally, the timing was influenced by anticipated delays in securing approvals from Chinese regulatory authorities due to the Golden Week holiday.
The issuance aims to prevent potential mandatory takeover obligations under Singapore's Takeovers Code, ensuring that the subscription does not trigger such a requirement.
All acquisition conditions have been fulfilled, with the completion expected around Oct. 25, pending further approvals from PRC governmental agencies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。